This publication summarises a session from the virtual 2021 Goodfellow Symposium. Speakers from Canada and Australia discussed the prescription weight loss medication, liraglutide 3mg. Key topics included bodyweight regulation and the central effects of liraglutide 3mg in energy homeostasis and appetite regulation, as well as efficacy and safety in different populations, concluding with a case study. The Goodfellow Symposium is a primary care symposium designed for GPs, urgent care physicians, nurses, nurse practitioners and registrars. This Goodfellow session and write up was supported by Novo Nordisk.
Download PDF